Jubilant Pharmova has announced its financial results for the second quarter and half year ended September 30, 2026. The company reported a consolidated revenue of ₹2,370 crore for Q2 FY27, marking a significant 21% increase year-on-year, driven by broad-based growth across its business segments. EBITDA stood at ₹255 crore, while reported PAT was ₹31 crore.
Jubilant Pharmova Q2 FY27 Financial Highlights
Jubilant Pharmova Limited today announced its financial results for the quarter and half year ended September 30, 2026. The company showcased robust performance with a consolidated revenue of ₹2,370 crore for the second quarter (Q2’FY27), reflecting a strong 21% year-on-year growth. This growth was broad-based across all its business segments, with particular strength in the CDMO Sterile Injectables business.
For the same quarter, EBITDA was reported at ₹255 crore, and the reported Profit After Tax (PAT) stood at ₹31 crore. The company noted that while EBITDA margins declined year-on-year, this was primarily due to the unavailability of high-margin SPECT radiopharmaceutical products and increased operating expenses, including remediation costs at the CMO Montreal facility.
Half-Yearly Performance (H1’FY27)
In the first half of FY27 (H1’FY27), Jubilant Pharmova’s revenue grew by 19% year-on-year to ₹4,599 crore. EBITDA for the period was ₹523 crore, and reported PAT stood at ₹87 crore. Similar to the quarterly results, EBITDA margins for the half-year also saw a decline due to the factors mentioned above, alongside increased depreciation and finance costs.
Segmental Performance Highlights
The press release detailed strong revenue growth in CDMO Sterile Injectables, driven by technology transfer revenues. The Radiopharma business saw growth in Ruby-Fill® installs and progress in new PET and SPECT products. The Allergy Immunotherapy segment also showed revenue growth. The company highlighted the release of Commercial SPECT radiopharmaceutical products from CMO Montreal and new agreements in the PET imaging space.
Significant developments also included the signing of a master services agreement with a large innovator pharma company for an oncology product and advancements in the Proprietary Novel Drugs business, with initial clinical data from JBI-802 presented. The company also announced successful fundraising of ₹800 crore through Non-convertible debentures to be used for debt refinancing and capex.
Source: BSE
